INTRODUCTION
The future of biobanks is often uncertain due to infrequent or sporadic funding through public or private grants. 1, 2 Funding for biobanks can simply expire or be withdrawn if the productivity or output of the biobank does not reach its anticipated potential. 3 A survey of biobank administrators (representing 456 biobanks) found that 2 of the most pressing issues for biobanks are the lack of funding to exist indefinitely and the absence of planning for what will happen when the banks close. 2 Moreover, the survey found that 40.3% of biobank administrators consider the loss of funding to be a "massive concern" and 30.6% reported it being a "moderate concern." 2 Despite the funding insecurity, only approximately 26% of biobanks reported having a written plan for the handling of biospecimens and data in the event of biobank closure. 2 The Organisation for Economic Co-operation and Development's international guidelines concerning biobanks and genetic research databases recommend that each biobank make a plan to either destroy biospecimens or transfer them to another facility if the current bank closes. 4 The guidelines further specify that a biobank should only transfer their biospecimens or data to equivalent institutions with the resources to appropriately handle the materials. 4 The Organisation for Economic Co-operation and Development thus holds the closing biobank responsible for ensuring that the future facility can adequately manage the biospecimens and data. The European Genetic Alliances' Network guidelines add that the transfer of donor biospecimens must be restricted to institutions that comply with the terms of the original informed consent document. 5 When the Armed Forces Institute of Pathology biobank, which housed 90 million samples dating back to 1862, faced closure in 2005, The National Defense Authorization Act of 2008 created a separate body, The Joint Pathology Center, to house the biospecimens and data. 6, 7 The Joint Pathology Center did not retain the original consent forms and it is highly unlikely that the consent forms authorized the transfer of biospecimens to another institution or the use of biospecimens for educational or research purposes. 6 This case study shows the ethical dilemmas that arise from the transfer of biobank samples, especially when informed consent for this transfer is not obtained.
Although guidelines exist and biobank administrators are concerned about the possibility of bank closure, to our knowledge it is not known what biospecimen donors prefer in the event of bank closure. Previous survey and focus group studies that asked potential and actual donors about the preferred research use of their biospecimens found that biospecimen donors prefer local and nonprofit researchers to pharmaceutical/for-profit and international researchers. [8] [9] [10] [11] Whether these preferences apply to bank closure is unknown. Therefore, we queried oncology biospecimen donors regarding the destruction or transfer of their biological materials after biobank closure as well as the type of biobank they would prefer to receive their biospecimens.
MATERIALS AND METHODS
Oncology biospecimen donors at the Winship Cancer Institute, the Anesthesia Preoperative Assessment Clinic of the Emory University Hospital, and the Georgia Cancer Center for Excellence at Grady Memorial Hospital were approached to participate in the current study. Any patient who had previously donated their biospecimens for research purposes was eligible to participate in the interview. The interview was created by the research team based on a thorough literature review. It was cognitively tested with 7 biospecimen donors in September 2016 for clarity and completeness of topics. The first section of the final interview consisted of 4 open-ended questions: 1) what donors would want to happen to their biospecimens and information in the event of bank closure; 2) would they want to be notified; 3) how they would feel; and 4) would closure affect their trust in medical research. This section was qualitatively coded by one of the authors (S.C.A.) with the original code book checked by a second author (R.D.P.). The second section presented 5 options for the handling of biospecimens in the event of bank closure: 1) transfer to a local academic biobank; 2) transfer to a national biobank; 3) transfer to a biobank based outside of the United States; 4) transfer to a for-profit/pharmaceutical biobank; or 5) destruction of their donated biospecimens. A script was used to briefly explain the different types of biobanks, with "banks outside of the United States" described last. After the investigator read the script, donors were asked to indicate which options they found absolutely unacceptable and then to rank the options they found acceptable from most preferred to least preferred. Given that participants were asked to only rank acceptable options, the participant-reported ranks (1 for most preferred to 5 for least preferred) were scaled to sum to 1 and more preferred ranks were given a larger weight. The weighted scores were the reverse order of their recorded rank divided by the sum of the ranks. For example, if a participant's responses were 1-2-3-4-5, the associated weighted scores were 5/15-4/15-3/15-2/15-1/15; if a participant's responses were 1-2-3 (with 2 unranked options), the associated weighted scores were 3/6-2/6-1/6. Five donors refused to rank or listed 2 of the options as equal and therefore their responses were counted as missing (93 donors available).
Statistical Analysis
Binary endpoints, such as trust in medical research and the acceptability of transfer to biobanks/destruction of biospecimen, were compared across categorical variables using chi-square tests or Fisher exact tests, where appropriate, and across numeric variables such as age using analysis of variance. Continuous endpoints, such as the scaled preference scores, were compared across categorical variables using analysis of variance, and across continuous variables using the Pearson correlation coefficient. Multivariable linear regression models for scaled scores were fit as a function of patient demographics. Significance was established at an alpha of .05, and the analysis was performed using SAS statistical software (version 9.4; SAS Institute Inc, Cary, NC). The study was approved by the Emory University Institutional Review Board and verbal consent was obtained from all participants.
RESULTS
Of the 105 biospecimen donors approached, 7 donors refused (7%) and 98 donors (93%) agreed to participate and were included in the current study. Demographics of the donors are described in Table 1 .
In response to the open-ended questions, the majority of biospecimen donors (62 of 83 donors who expressed a preference; 75%) preferred to have their biological materials transferred to another biobank if their bank closed. A minority of donors (34 of 98 donors; 35%) wanted to be notified of the closure of their biobank, with telephone or e-mail being the preferred notification method (22 of 32 donors; 69%). The majority of donors (54 of 93 donors; 58%) would not care if their biobank closed, whereas other participants indicated they would be sad/disappointed (29 of 93 donors; 31%) or frustrated and/or angry (3 of 93 donors; 3%). The overwhelming majority of donors (83 of 98 donors; 88%) responded that biobank closure would not reduce their trust in medical research.
As detailed in Table 2 , the most unacceptable option for the handling of donors' biological materials after biobank closure was the transfer of their biospecimens to a for-profit/pharmaceutical biobank (39 of 98 donors; 39.8%). Moreover, a moderate number of donors (31 of 98 donors; 31.6%) viewed the transfer of their biospecimen to a biobank based outside of the United States as unacceptable, whereas a few donors (8 of 98 donors; 8%)
found the transfer of their biospecimen to a national biobank unacceptable. Only 1 donor each viewed the transfer of his or her biospecimen to a local academic biobank (1 of 98 donor; 1%) or its destruction (1 of 98 donor; 1%) as unacceptable. When asked to rank the options they deemed acceptable, donors indicated that the most preferred option was transfer to a local academic biobank (mean scaled score, 0.36) followed by transfer to a national biobank (mean scaled score, 0.27), transfer to an international biobank (mean scaled score, 0.14), destruction of the biospecimen (mean scaled score, 0.13), and transfer to a for-profit/pharmaceutical biobank (mean scaled score, 0.093) ( Table 2) .
Nonwhite participants were more likely to view the transfer of their biospecimen to a for-profit/pharmaceutical biobank (60.9% vs 33.3%; P 5 .018), an international biobank (52.2% vs 25.3%; P 5 .015), or a national biobank (21.7% vs 4.0%; P5 .016) as unacceptable compared with white participants. Participants who were not employed at the time of the interview (25 of 64 donors; 39%) were more likely to believe the transfer of their biospecimen to an international biobank was unacceptable compared with participants who were working full or part time (6 of 34 donors; 18%) (P 5 .030). Donors who were employed full or part time preferred international biobanks more than unemployed donors (mean scaled score of 0.18 vs 0.13; P 5 .046). However, when employment was controlled for income and educational level, employment status was no longer found to be a significant determinant (Table 3 ).
DISCUSSION
The current study regarding the views of biospecimen donors provides some guidance for cancer biobank Original Article administrators concerning the preferred handling of biospecimens if a biobank closes. These donors preferred transfer to another bank, preferably another academic or national bank, with for-profit and international banks not preferred. This result was magnified by the novel finding that for-profit and international bank transfers were viewed as absolutely unacceptable by approximately onethird of the donors. These results agree with previous findings that donors are concerned with the use of their biospecimens in international and pharmaceutical/for-profit research. [8] [9] [10] [11] A previous survey found that a significant minority of donors (117 of 279 donors; 42%) believed broad consent is unacceptable for pharmaceutical industry-sponsored research. 8 Another survey found that biospecimen donors were most willing to allow local university researchers (263 of 273 donors; 96.3%) to use their biospecimen for research followed by other US institutional researchers (245 of 273 donors; 89.7%), international researchers (215 of 273 donors; 78.8%), pharmaceutical industry researchers (176 of 273 donors; 64.5%), and "for-profit" researchers (124 of 273 donors; 45.4%). 9 These combined findings suggest that an educational program is needed to alert the public to the importance of collaboration with for-profit pharmaceutical companies and international partners to promote research.
The sample in the current study found further evidence of some ethnic differences in preferences regarding biospecimen use. In the current study sample, white donors were more likely to find the transfer of their biospecimen to both pharmaceutical/for-profit and international institutions acceptable compared with nonwhite donors. In a similar study of biospecimen donors, Pentz et al found that whites were more likely to allow their biospecimens to be used outside of the United States compared with nonwhites. 11 Moreover, Helft et al found that whites were more likely to permit the use of their biospecimens in unlimited future research compared with nonwhites. 9 These ethnic differences provide another rationale for a transfer policy to biobanks comparable to the original, because consent had been obtained for the original bank.
We found that approximately one-third of donors (34 of 98 donors; 35%) wished to be notified if their biobank closed or would be sad and/or disappointed (29 of 93 donors; 31%), with a very few feeling frustrated and/or angry (3 of 93 donors; 3%). It is somewhat surprising that when simply asked, "Would you want to be notified if your biobank closed," only slightly more than one-third of donors answered "yes." Nor would biobank closure reduce trust in medical research. However, donors were asked these questions before we presented them with the option of a transfer to international or for-profit banks, and therefore the fact that one-third of oncology biospecimen donors found such transfers to be absolutely unacceptable must be taken into consideration. Again, educational efforts might be helpful. In any case, these findings support the imperative for biobanks to have wellthought out guidelines in the case of closure.
Further research should investigate the differences in biobanking preferences based on racial and employment variables, particularly because employment was not found to be a significant determinant of preference when income and education were controlled for. Because 23 patients did not provide information regarding income, the lack of significance may be due to the smaller sample size, although this should be investigated. A better understanding into if and why different demographic groups differ could better equip tissue bank investigators and administrators when incorporating tissue donor preferences into their research protocols and policies. Moreover, because the current study only included donors to academic biobanks, a multi-institutional follow-up study that includes donors to different types of banks (community, for-profit, national, or international banks, etc) is needed to determine whether the type of bank to which one has donated influences one's perception of the best option for handling tissue at the time of bank closure.
Limitations
One possible limitation of the current study is that we did not know whether participants perceived the international biobanks to be academic or for-profit/pharmaceutical. If asked, the researchers explained that international biobanks could be either academic or for-profit; however, the novelty of the concept for the majority of participants may have prevented a full understanding of the term. This possible source of ambiguity may have influenced the participants' perceptions of international banks and their relationship to the other alternative biobanking options. Moreover, the current study was based at an academic medical center and its affiliated sites, which may have influenced the donors' preferences for academic banks. This factor combined with the relatively small number of interviewees reduces generalizability. However, to the best of our knowledge, the current study is the first to seek donors' views.
